Home RXi Pharmaceuticals Announces Completion of Enrollment in Second Phase 1 Trial for RXI-109 Program
 

Keywords :   


RXi Pharmaceuticals Announces Completion of Enrollment in Second Phase 1 Trial for RXI-109 Program

2013-01-31 09:52:58| Biotech - Topix.net

RXi Pharmaceuticals Corporation , a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that its second Phase 1 study with their anti-scarring drug, RXI-109, for the management of surgical and hypertrophic scars and ... (more)

Tags: program trial phase completion

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11How Japan's youngest CEO transformed Hello Kitty
31.10Unicharm to Expand in Africa
31.10Essity Named Diversity Leader by Financial Times
31.10Maxcess to Make FIFE Guiding Products in Mumbai
More »